HC Wainwright Cuts Rockwell Medical (NASDAQ:RMTI) Price Target to $2.00

Rockwell Medical (NASDAQ:RMTI) had its price target trimmed by HC Wainwright from $2.50 to $2.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.05) EPS, Q1 2027 earnings at ($0.01) EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.01 EPS, Q4 2027 earnings at $0.02 EPS and FY2027 earnings at $0.04 EPS.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $2.00.

Rockwell Medical Price Performance

Shares of Rockwell Medical stock opened at $0.93 on Monday. The firm has a market cap of $36.77 million, a PE ratio of -6.22 and a beta of 1.70. Rockwell Medical has a 12-month low of $0.78 and a 12-month high of $2.10. The company has a quick ratio of 3.63, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The company’s fifty day simple moving average is $1.00 and its two-hundred day simple moving average is $1.03.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). The firm had revenue of $18.35 million for the quarter, compared to the consensus estimate of $18.58 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%. As a group, equities analysts expect that Rockwell Medical will post 0.03 EPS for the current year.

Hedge Funds Weigh In On Rockwell Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Panagora Asset Management Inc. bought a new position in Rockwell Medical in the second quarter worth about $41,000. XTX Topco Ltd boosted its position in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after acquiring an additional 46,029 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Rockwell Medical during the 4th quarter worth approximately $84,000. GSA Capital Partners LLP grew its holdings in shares of Rockwell Medical by 635.1% during the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after acquiring an additional 141,672 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after acquiring an additional 41,668 shares in the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware?domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.